Assuntos
Surtos de Doenças , Leishmania infantum/isolamento & purificação , Leishmaniose Visceral/epidemiologia , Abuso de Substâncias por Via Intravenosa/epidemiologia , Animais , Humanos , Leishmaniose Visceral/parasitologia , Espanha/epidemiologia , Abuso de Substâncias por Via Intravenosa/parasitologiaRESUMO
BACKGROUND: To know the prevalence of Toxoplasma gondii latent infection in HIV-1 infected patients and to compare it with the prevalence in a group of parenteral drug users, non-infected by HIV. METHODS: We study 255 HIV-1 patients revised in our hospital in the last 6 years. The control group were 116 drug addicts non-infected by HIV followed in an educational program of deshabituation. We tested IgG anti-toxoplasma by enzymatic inmunoessay (MEIA). An IgG plasma value of 6UI/ML or more was an indicative of toxoplasma previous infection. We used Chi Square and Yatchts correction tests for the statistical analysis, settling down a significance point of 95%. RESULTS: We founded 36.7% positive IgG anti-toxoplasma in the group on HIV-1 infected patients, non drugs addicts, against 30.9% in the group of HIV-1 drug addicts patients. (OR 0.77; 0.35 < OR < 1.66). The control group showed a Toxoplasma seroprevalence of 26.7%, without statistically significant against the drug addicts HIV group (OR = 1.55; 0.93 < OREGON < 2.59). CONCLUSIONS: The seroprevalence of Toxoplasma gondii latent infection in our study was similar to the european results. We didn't found a higher prevalence in HIV-1 patients than in patients non infected by HIV-1.